Seastar Medical Holding Corp (ICUCW) Stock Price & Analysis

Seastar Medical Holding Corp (ICUCW) fell 22.53% to USD 0.01 as of June 10, 2026 at 15:45 UTC, according to Nexqual real-time market data.

ICUCW last closed at USD 0.02; the session ranged USD 0.01–0.02 on volume of 84,560 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.02 (NCM). Source: Nexqual, June 10, 2026 at 15:45 UTC.

Key Statistics (as of June 10, 2026 at 15:45 UTC)

Technical Analysis (ICUCW)

Nexqual's technical model rates ICUCW "SELL" based on 3 bullish and 5 bearish signals across 67 daily candles, as of June 10, 2026 at 15:45 UTC.

Analyst Ratings (ICUCW)

Wall Street analysts rate ICUCW "None", per Nexqual as of June 10, 2026 at 15:45 UTC.

Earnings (ICUCW)

Source: Nexqual, June 10, 2026 at 15:45 UTC.

Financials & Fundamentals (ICUCW)

Source: Nexqual, June 10, 2026 at 15:45 UTC.

Financial Health Score (ICUCW)

Nexqual rates Seastar Medical Holding Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 15:45 UTC.

Ownership (ICUCW)

Source: Nexqual, June 10, 2026 at 15:45 UTC.

Leadership (ICUCW)

Seastar Medical Holding Corp is led by Eric Schlorff (age 52), CEO, Treasurer, President & Executive Director, per Nexqual as of June 10, 2026 at 15:45 UTC.

Major Backers & Investors (ICUCW)

Notable institutional backers of Seastar Medical Holding Corp include Boothbay Fund Management, LLC, Linden Advisors LP, Goldman Sachs, according to Nexqual as of June 10, 2026 at 15:45 UTC.

Active Investors

Source: Nexqual, June 10, 2026 at 15:45 UTC.

From Seastar Medical Holding Corp's Latest SEC 10-K Filing (filed 2026-03-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Our success depends in large part on our ability to protect our proprietary technology, including our SCD technologies, and to operate without infringing the proprietary rights of third parties.   17 Table of Contents   The term of individual patents depends on the legal term of the patents in the countries in which they are obtained.
• In consideration for such exclusive license, during the term of the UOM License Agreement, we agreed to pay the UOM a royalty fee equal to 1% of net sales as well as a one-time milestone payment of $0.1 million upon FDA approval of the first licensed product under the license (paid in 2024), and to reimburse patent costs.
• On February 21, 2024, we announced a final Approval Order for the HDE, which allows us to commercialize QUELIMMUNE.   Clinical Progression   NEUTRALIZE-AKI Design   We are actively enrolling and treating patients in a pivotal clinical trial of the SCD for the treatment of AKI in adults, an indication awarded BDD by the FDA in April 2022.
• We also rely on know-how, confidentiality agreements, license agreements and other agreements to establish and protect our proprietary rights.

Partnerships

• In addition to the Supply Agreement with FUSA, we are developing a second source for both adult and pediatric cartridges, which will enable us to better manage potential supply disruptions.   Additionally, use of the SCD in hospital settings requires the administration of RCA and calcium replacement into CRRT circuitry for safe and effective use.
• If during such period, we elect to promote and sell the SCD through distributors, we will be required to provide FUSA with a right of first refusal to be our exclusive distributor of the SCD in the United States and its territories, provided that the SCD is not promoted or sold in a manner that is incompatible with any devices manufactured and/or sold by FUSA or its affiliates.   On December 27, 2022, we entered into a license and distribution agreement with Nuwellis.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:45 UTC. This page is informational and not investment advice.